Cardiometabolic 'cluster' signals still point up - but the edge is already leaking
The Opportunity
Upstream mechanism sign is positive and the direction is LONG via proxy (XBI/IHE) - the intuitive read is that cardiometabolic clinical momentum can reprice biotech basket risk. The reason this remains directionally bullish is simple: credible clinical progress is the scarce input that expands valuation bandwidth in biotech.
The Timing
This is INVESTIGATE because it sits in propagation_monitor with spreading/decaying edge. To convert back to a TRADE-quality window you would need a fresh, issuer-specific, date-stamped catalyst that is still contained (not a broad sector theme already in Tier-1 circulation). Without that, you are fighting a crowded narrative in a Mixed 68 regime with crosswind risk 74.
The Evidence
The upstream routing explicitly flags Tier-1 presence and a high distinct-domain count, which is why the edge is labelled DECAYING. Freshness is not provided at the signal level here. Hydrated evidence links are absent in this run, so treat this as a lifecycle call (edge closing) rather than an under-the-radar document-based trade.